Hemispherx BioPharma (HEB)

[TommyBoyTrader9460]

$heb.. .239...buying volume pouring in now...

[whytestocks]

News: $HEB Hemispherx To Be Transparent on the Development of Ampligen and Announced Significant Progress

NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Hemispherx Biopharma, Inc. (NYSE: HEB) , a specialty pharmaceutical company, eng...

Find out more https://marketwirenews.com/news-releases/hemispherx-to-be-transparent-on-the-development-of-ampligen-and-announced-significant-progress-8091938.html

[TommyBoyTrader9460]

$heb.. .215... Up 4 percent premarket and climbing...

[pberger]

This utter crap is resuming trading now @$0.205, indeed, NO value here.

[$avvyPenny$tockInvestor™]

May get a nice bounce tomorrow.

[TommyBoyTrader9460]

$heb..28 thousand on the bid at .22 now...looks to continue higher ah...

[TommyBoyTrader9460]

$heb...strong buy continues.. .224 now...

[ClayTrader]

* * $HEB Video Chart 04-30-2019 * *

Link to Video - click here to watch the technical chart video

[pberger]

Who cares as it's down 35% from PM, pure turd, indeed.

[TommyBoyTrader9460]

$heb....2193...up 7 percent ah...

[TommyBoyTrader9460]

$heb..strong buying continues...looking for close above .25...

[pberger]

Such a bleeding CRAP, this is pure TURD, no value here!

[$avvyPenny$tockInvestor™]

Yes sir they do.

[TommyBoyTrader9460]

$heb... .235..bids holding strong...flippers look done..time to criss .25 and fly...

[TommyBoyTrader9460]

$heb...cross back over .25and we should rezlly see some fireworks...

[TommyBoyTrader9460]

$heb....24...shorts are on the run...

[TommyBoyTrader9460]

$heb...would not be shocked to see .30 plus ah....

[TommyBoyTrader9460]

$heb.. 245 and climbing quickly...

[The Dutchess]

It is

[Golden Cross]

Picking up steam here

[TommyBoyTrader9460]

$heb...all out blitz onthe ask now... .235 and climbing...

[TommyBoyTrader9460]

$heb...ask getting hammered..crossing .23 now...

[TommyBoyTrader9460]

$heb...strong bids at .22 now..

[TommyBoyTrader9460]

$heb.. .227..buying volume pouring in now...

[TommyBoyTrader9460]

$heb...huge news out today..thanks for posting it...

[TommyBoyTrader9460]

Great job cross!...$heb...strong buying continues here...

[Golden Cross]

Significant_Progress_in_its_Ampligen_Ovarian_Cancer_Program_Hemispherx (AMEX:HEB)

Today : Tuesday 30 April 2019

Click Here for more Hemispherx Charts.
(NYSE American: HEB) — Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, announced today significant progress in its Ampligen recurrent ovarian cancer program at the University of Pittsburgh Medical Center (UPMC) under the leadership of the principal investigator, Robert Edwards, MD. The ovarian cancer program is being funded in part by an Ovarian Cancer Specialized Program of Research Excellence (SPORE) from the National Institutes of Health (NIH), which is supporting a Phase 1/2 study of intraperitoneal chemo-immunotherapy in recurrent ovarian cancer.
Recently, an interim report was received by Hemispherx that summarizes results related to some of the laboratory objectives of this study which include characterization of the local immune responses during chemo-induced cell death as measured by serial assessment of peritoneal fluid cellular phenotypes and chemokine patterns.

"Ampligen has the potential to be clinically significant because a robust killer T-cell population in the tumor microenvironment without attracting Treg cells is important to help optimize checkpoint blockade induced tumor shrinkage," said Dr. Edwards, chair of gynecologic services at Magee-Women’s Hospital of the University of Pittsburgh School of Medicine (UPMC), Professor of Obstetrics, Gynecology & Reproductive Services at UPMC, a world-class expert in ovarian cancer and a pioneer in Ampligen research.

Currently, a second ovarian cancer clinical trial at UPMC is beginning to accrue patients. This is a Phase 2 investigator-sponsored trial fully funded by an industry grant that will evaluate Ampligen in combination with the checkpoint blockade drug, pembrolizumab. This much larger trial will test the combination of Ampligen and pembrolizumab in subjects with advanced recurrent ovarian carcinoma. For more details regarding the collaboration and protocol, please go to the NIH-sponsored website, https://clinicaltrials.gov/ct2/show/NCT03734692.

“Ovarian cancer is projected to kill 152,000 this year worldwide. Recurrent ovarian cancer is a dire unmet medical need. Working with the University of Pittsburgh, we are able to team up and focus world-class science on developing a meaningful combination therapy with the potential to save the lives of women who may be out of therapeutic options,” declared Thomas K. Equels, CEO of Hemispherx.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers. Hemispherx's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, Hemispherx believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® already conducted include studies of the potential treatment of cancer patients with renal cell carcinoma and malignant melanoma. These and other potential uses will require additional clinical trials to generate the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Contacts:

Hemispherx Biopharma, Inc.
Phone: [phone]
Email: [e-mail]
Or
LHA Investor Relations
Miriam Weber Miller
Senior Vice President
Phone: [phone]
Email: [e-mail]

[Golden Cross]

Thanks for the update...looking stronger here...going to sticky that PR in a minute...GL

[TommyBoyTrader9460]

$heb...great buy!...looks good to test hod before close...

[Golden Cross]

That was a good retrace today to get a entry

[Golden Cross]

tried some 21's here...GL

[TommyBoyTrader9460]

$heb...the psar just flipped positive...its go time...

[Golden Cross]

Watching close here

[TommyBoyTrader9460]

$heb...nice churn through shares here...looks to test hod this afternoon...

[Golden Cross]

looks like it!

[TommyBoyTrader9460]

$heb...flippers drying up...about to run even higher...

[TommyBoyTrader9460]

$heb...shorts screwed here...could see .50today...

[TommyBoyTrader9460]

$heb...huge news out...just loaded...

[whytestocks]

News: $HEB Hemispherx Biopharma Announces Significant Progress in its Ampligen Ovarian Cancer Program

OCALA, Fla., April 30, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, announced today significant progress in its Ampligen recurrent ovaria...

Got this from https://marketwirenews.com/news-releases/hemispherx-biopharma-announces-significant-progress-in-its-ampligen-ovarian-cancer-program-8083594.html

[ClayTrader]

* * $HEB Video Chart 04-29-2019 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $HEB Video Chart 04-26-2019 * *

Link to Video - click here to watch the technical chart video

[Richard2]

There is still a lot of coverage on this stock, that's a positive sign.

[Richard2]

I don’t see any choice but to R/S, I think they should be more open to the otcqb, but for debt equity financing the terms are much better on higher exchanges. I bought in because I believe in the drug. The cancer results should get this moving upwards, unfortunately they still need the cash to go through about two years of trials as it’s unlikely the FDA will fast-track anything for this company.

[carldfw]

I put in 250$ incase they dont rs. When the regular ihub clowns show up to keep the price up you can bet its done. I bought in in 2008 lost some but bioelectronics paid off. So now I mainly buy shells and wait. This i will buy into after the rs.

[Richard2]

They might be worth something one day, but I think this stock still has worse times ahead before anything positive happens. I’m holding my few shares.

[carldfw]

Always a good pump and dump voting for the r/s?

[ClayTrader]

* * $HEB Video Chart 04-10-2019 * *

Link to Video - click here to watch the technical chart video

[carldfw]

Hard to tell its moving up good. I only have 2500 shares.

[HORUS]

Lmao. Me too from .50 to 4.54

[ClayTrader]

* * $HEB Video Chart 04-09-2019 * *

Link to Video - click here to watch the technical chart video